Barclays
MJN

Barclays’s Mead Johnson Nutrition Company MJN Stock Holding History

Barclays’s Portfolio MJN Stock Details MJN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-41,000
Closed -$3.65M – 7204
2017
Q1 		$3.65M Buy
41,000
+18,700
+84% +$1.54M ﹤0.01% 1564
2016
Q4 		$1.58M Buy
22,300
+5,200
+30% +$388K ﹤0.01% 2321
2016
Q3 		$1.35M Sell
17,100
-3,000
-15% -$256K ﹤0.01% 2345
2016
Q2 		$1.82M Sell
20,100
-8,700
-30% -$737K ﹤0.01% 2094
2016
Q1 		$2.42M Sell
28,800
-700
-2% -$52.1K ﹤0.01% 1749
2015
Q4 		$2.3M Sell
29,500
-1,500
-5% -$118K ﹤0.01% 1913
2015
Q3 		$2.17M Buy
31,000
+8,000
+35% +$658K ﹤0.01% 2054
2015
Q2 		$2.07M Buy
23,000
+15,700
+215% +$1.51M ﹤0.01% 2196
2015
Q1 		$730K Sell
7,300
-122,700
-94% -$12.4M ﹤0.01% 3257
2014
Q4 		$13M Sell
130,000
-92,300
-42% -$9.2M 0.01% 1016
2014
Q3 		$21.3M Buy
222,300
+115,000
+107% +$10.9M 0.02% 684
2014
Q2 		$9.98M Buy
107,300
+77,900
+265% +$6.81M 0.01% 1159
2014
Q1 		$2.44M Sell
29,400
-73,300
-71% -$5.94M ﹤0.01% 2357
2013
Q4 		$8.52M Buy
102,700
+17,000
+20% +$1.38M 0.01% 1374
2013
Q3 		$6.34M Sell
85,700
-53,800
-39% -$4.03M 0.01% 1492
2013
Q2 		$11.1M Buy
+139,500
New +$11.2M 0.01% 1014

Other funds holding MJN

PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $22.7B AUM
FNBOO
First National Bank of Omaha Omaha, Nebraska $3.55B AUM 27.24% 1-Year Est. Return
LFAS
Level Four Advisory Services Dallas, Texas $3.54B AUM 37.12% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return
CPIG
Chicago Partners Investment Group Chicago, Illinois $5B AUM 26.84% 1-Year Est. Return
WEC
Winslow Evans & Crocker Boston, Massachusetts $528M AUM 30.99% 1-Year Est. Return

Barclays's MJN Position: Q2 2017 in Review

Barclays sold out of Mead Johnson Nutrition Company (MJN) in Q2 2017, closing a stake of 881,402 shares — an estimated $78.5M sold.

Barclays first reported a position in MJN in Q2 2013 and held it in 16 quarters. The position peaked at $78.5M in Q1 2017. 7 funds tracked by Wall St. Rank hold MJN as of Q2 2017.

  • Barclays reported no remaining Mead Johnson Nutrition Company position as of Q2 2017 after selling out during the quarter.
  • Barclays sold 881,402 Mead Johnson Nutrition Company shares in Q2 2017, an estimated $78.5M.
  • Barclays first reported a position in Mead Johnson Nutrition Company in Q2 2013 and held it in 16 quarters.
  • Barclays's Mead Johnson Nutrition Company position peaked at $78.5M in Q1 2017.
  • 7 funds tracked by Wall St. Rank held Mead Johnson Nutrition Company as of Q2 2017.

Based on Barclays's 13F filing for Q2 2017, filed 14 Aug 2017.